MET and colorectal carcinoma: Moreover, anti-EGFR antibodies have demonstrated high activity in patients with metastatic BRAF class 3–mutated CRC while showing low activity in those harboring class 2 mutations.6,20 Notably, other potential targets reported to be active in some cases of BRAF class 3–mutated tumors, such as MET, and erlotinib off-target effects that may contribute to cell growth inhibition were not explored in this study and may be object of further investigation in future research.6